Cancer kinases and its novel inhibitors: Past, present and future challenges
Publication Type:Journal Article
Source:Current Drug Targets, Bentham Science Publishers B.V., Volume 16, Number 11, p.1233-1245 (2015)
Cancer kinome is now well organized as an important target for a new class of cancer drugs. There are more than 500 members in the kinase family in which some of them are clinically analysed, while the rest are under investigation for potential therapeutic applications. Phosphorylation, major function of kinases is one of the most significant signal transduction mechanism in which intercellular signals regulate intracellular processes like ion transport, hormone responses and cellular proliferation. Any deregulation of kinase function may lead to tumor progression and other disorders such as immu-nological, neurological, metabolic including also infectious diseases. This led to the necessity in the development of kinase inhibitors as therapeutic agent. Herein we discuss about different types of kinases and their inhibitors in various types of cancers. This review portrays a broad overview of the origin of kinases, discovery, the characterization and mode of action of kinase inhibitors in cancer therapy. © 2015 Bentham Science Publishers.
cited By 0
Cite this Research Publication
Related Research Publications
- Simultaneous inhibition of aberrant cancer kinome using rationally designed polymer-protein core-shell nanomedicine
- All stressed out without ATM kinase
- Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia
- A positive feedback loop involving Erk5 and Akt turns on mesangial cell proliferation in response to PDGF
- Janus kinase inhibitors: Jackpot or potluck?